-$0.53 Earnings Per Share Expected for Syros Pharmaceuticals, Inc. (SYRS) This Quarter
Equities analysts expect Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) to post earnings of ($0.53) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Syros Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.52) and the lowest estimate coming in at ($0.54). Syros Pharmaceuticals posted earnings per share of ($0.65) in the same quarter last year, which would indicate a positive year over year growth rate of 18.5%. The firm is scheduled to announce its next quarterly earnings report on Monday, November 13th.
On average, analysts expect that Syros Pharmaceuticals will report full-year earnings of ($2.08) per share for the current financial year, with EPS estimates ranging from ($2.13) to ($2.00). For the next fiscal year, analysts anticipate that the firm will post earnings of ($2.97) per share, with EPS estimates ranging from ($3.79) to ($2.55). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Wednesday, August 9th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.03.
Several equities analysts have commented on the company. JMP Securities cut Syros Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, August 10th. Wedbush reaffirmed an “outperform” rating and issued a $22.84 price target (down previously from $25.00) on shares of Syros Pharmaceuticals in a report on Thursday, August 10th. Cowen and Company reaffirmed a “buy” rating on shares of Syros Pharmaceuticals in a report on Wednesday, August 9th. Zacks Investment Research cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, Cann reaffirmed a “buy” rating and issued a $28.00 price target on shares of Syros Pharmaceuticals in a report on Monday, August 21st. Two equities research analysts have rated the stock with a sell rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $26.37.
Syros Pharmaceuticals (SYRS) traded up 3.80% on Thursday, hitting $17.48. The stock had a trading volume of 119,572 shares. Syros Pharmaceuticals has a one year low of $10.22 and a one year high of $24.38. The stock’s market cap is $459.02 million. The stock’s 50 day moving average is $15.91 and its 200 day moving average is $15.91.
TRADEMARK VIOLATION WARNING: This article was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/10/12/0-53-earnings-per-share-expected-for-syros-pharmaceuticals-inc-syrs-this-quarter.html.
In other news, insider Eric R. Olson sold 12,500 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $21.85, for a total value of $273,125.00. Following the sale, the insider now directly owns 12,500 shares in the company, valued at approximately $273,125. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Eric R. Olson sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $23.59, for a total value of $58,975.00. Following the completion of the sale, the insider now owns 2,500 shares in the company, valued at $58,975. The disclosure for this sale can be found here. Over the last quarter, insiders sold 21,564 shares of company stock worth $476,803. Corporate insiders own 33.60% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. AWM Investment Company Inc. grew its stake in shares of Syros Pharmaceuticals by 155.8% in the 2nd quarter. AWM Investment Company Inc. now owns 121,624 shares of the company’s stock valued at $1,957,000 after purchasing an additional 74,074 shares during the period. California State Teachers Retirement System grew its stake in shares of Syros Pharmaceuticals by 131.3% in the 2nd quarter. California State Teachers Retirement System now owns 22,200 shares of the company’s stock valued at $357,000 after purchasing an additional 12,600 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Syros Pharmaceuticals by 11,253.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,559 shares of the company’s stock valued at $170,000 after purchasing an additional 10,466 shares during the period. Redmile Group LLC grew its stake in shares of Syros Pharmaceuticals by 2.2% in the 2nd quarter. Redmile Group LLC now owns 973,260 shares of the company’s stock valued at $15,660,000 after purchasing an additional 20,520 shares during the period. Finally, State Street Corp grew its stake in shares of Syros Pharmaceuticals by 176.7% in the 2nd quarter. State Street Corp now owns 169,497 shares of the company’s stock valued at $2,728,000 after purchasing an additional 108,250 shares during the period. Institutional investors own 59.61% of the company’s stock.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.